Trial Profile
90Y ibritumomab tiuxetan (Zevalin) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2012
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms ZENO
- 29 Jul 2011 New trial record